Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: March 28, 2011
Last updated: December 1, 2014
Last verified: November 2014
The general aim of this study is to investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with HER2-overexpressing, locally advanced or metastatic inflammatory breast cancer. The study will include patients who have and have not failed prior trastuzumab treatment.

Condition Intervention Phase
Breast Neoplasms
Drug: Afatinib once daily (OD)
Drug: Vinorelbine Weekly
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Clinical Benefit (CB) assessed by Complete Response (CR), Partial Response (PR) and Stable Disease (SD) for at least 6 months using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1) [ Time Frame: Every 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of participants with changes in vital signs and safety laboratory parameters [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Objective Response (OR) assessed by RECIST 1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1) [ Time Frame: Every 8 weeks ] [ Designated as safety issue: No ]
  • Duration of objective response, defined as the time from first objective response to the time of progression or death. [ Time Frame: Every 8 weeks ] [ Designated as safety issue: No ]
  • Progression Free Survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Safety assessed by the intensity and incidence of adverse events [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 26
Study Start Date: August 2011
Study Completion Date: November 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Afatinib once daily (OD)
Patients receive afatinib monotherapy once daily until progression of their disease
Drug: Afatinib once daily (OD)
Patient to receive afatinib monotherapy until progression of their disease
Drug: Vinorelbine Weekly
Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Female patients >=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer
  2. Locally advanced or metastatic disease
  3. Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1)
  4. For trastuzumab pre-treated patients, must have failed prior trastuzumab treatment
  5. Investigator-confirmed diagnosis of Inflammatory Breast Cancer
  6. Must have biopsiable disease

Exclusion criteria:

  1. Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population)
  2. Must not have received prior vinorelbine treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01325428

United States, California
1200.89.10001 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
United States, North Carolina
1200.89.10005 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
Australia, Victoria
1200.89.61002 Boehringer Ingelheim Investigational Site
East Bentleigh, Victoria, Australia
Australia, Western Australia
1200.89.61003 Boehringer Ingelheim Investigational Site
Perth, Western Australia, Australia
Hong Kong
1200.89.85201 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
Korea, Republic of
1200.89.82002 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1200.89.82001 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1200.89.66002 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
1200.89.66004 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
1200.89.66003 Boehringer Ingelheim Investigational Site
Chiangmai, Thailand
1200.89.66001 Boehringer Ingelheim Investigational Site
Hat-Yai, Songkhla, Thailand
1200.89.21601 Boehringer Ingelheim Investigational Site
Ariana, Tunisia
1200.89.21602 Boehringer Ingelheim Investigational Site
Sousse, Tunisia
United Kingdom
1200.89.44002 Boehringer Ingelheim Investigational Site
Bournemouth, United Kingdom
1200.89.44001 Boehringer Ingelheim Investigational Site
London, United Kingdom
1200.89.44003 Boehringer Ingelheim Investigational Site
London, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim Identifier: NCT01325428     History of Changes
Other Study ID Numbers: 1200.89  2010-024454-10 
Study First Received: March 28, 2011
Last Updated: December 1, 2014
Health Authority: Australia: Dept of Health and Ageing Therapeutic Goods Admin
Hong Kong: Department of Health
South Korea: Ministry of Food and Drug Safety (MFDS)
Thailand: Food and Drug Administration
Tunisia: Ministry of Public Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Inflammatory Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Pharmacologic Actions
Therapeutic Uses processed this record on February 08, 2016